The apex curt had earlier asked the Singh brothers to give it a plan as to how they would honour the arbitral award of Rs 3,500 crore granted by a Singapore tribunal against them and in favour of Japanese drug manufacturer Daiichi Sankyo.
A Delhi Court on Thursday sent former Ranbaxy promoter Singh brothers and three others to judicial custody till October 31 in the Religare fraud case. Malvinder and Shivender Singh along with Sunil Godhwani, Anil Saxena and Kavi Arora were produced before link judge Nishant Garg as Chief Metropolitan Magistrate Deepak Sehrawat was on leave.
A Delhi court Friday granted the police 4-day custody of former Fortis Healthcare promoters, Malvinder Singh, his brother Shivinder and three others, arrested for allegedly misappropriating funds of Religare Finvest Ltd (RFL), causing it losses of Rs 2,397 crore.
Former Ranbaxy promoter Shivinder Singh has been arrested by the Delhi Police in a cheating/fraud case of Rs 740 crores. Reports suggest Religare's ex-CMD Sunil Godhwani along with two others have also been arrested. The said arrests have been made by the Economic Offences Wing. Reportedly, a lookout notice has been issued against the other brother Malvinder Singh.
The Supreme Court on Friday expressed dissatisfaction over the replies filed by former Ranbaxy promoters Malvinder Singh and Shivinder Singh in response to its March 14 direction asking them to submit a concrete plan for paying Rs 4,000 crore to Daiichi Sankyo as directed by a Singapore tribunal.
The court’s directions came on an interim application by Japanese conglomerate Daiichi Sankyo, which had bought a majority stake in Ranbaxy in 2008
New Delhi: Former owners of Ranbaxy Laboratories Malvinder Singh and Shivinder Mohan Singh, have been asked by a Singapore court to pay damages worth $400 million (over Rs 2,500 crore) to Japan's Daiichi Sankyo Co.
New Delhi: The co-founder of Fortis Healthcare, Shivinder Mohan Singh, has sprung a surprise by renouncing the corporate world and joining a spiritual organisation. The 40-year-old responded to a higher calling and will soon be
Washington: A US class action lawsuit accusing India's Ranbaxy of large-scale deception on its generic drug applications puts a question mark on drug imports from India, the largest supplier of generic drugs to the US.The
May 6th, the judgment day of actor Salman Khan's hit-and-run case is not only critical for him but for several others who are associated with the megastar. As per a media reports, around 2000 crore
New Delhi: Sun Pharmaceutical Industries today said that its merger with Ranbaxy has been 'consummated' following receipt of requisite approvals, almost a year it announced the $4 billion deal.In a filing to the BSE, the
New Delhi: Drug major Sun Pharma is now a step closer to becoming the world's fifth-largest generic drug company, as the US Federal Trade Commission (USFTC) has given a conditional nod for the proposed $4-billion
Washington: An American federal trade regulator today imposed conditions on Sun Pharmaceuticals' acquisition of Ranbaxy on the grounds that the USD 4 billion proposed deal would likely be anti-competitive.The Federal Trade Commission (FTC) said pharmaceutical
New Delhi: Drug major Ranbaxy said that the US health regulator has "determined" that the Indian drug manufacturer has forfeited its 180 days exclusivity for stomach and esophagus problems treatment tablets."We have now received a
New Delhi: Drug maker Ranbaxy Laboratories has posted a net profit of Rs 477.75 crore for the quarter-ended September 30 due to strong topline, lower expenses and operational performance despite higher finance and tax cost,
New Delhi: Drug major Ranbaxy Laboratories has received the U.S. health regulator's approval to market a generic version of Novartis' Diovan tablets, used for treating high blood pressure and heart failure, in the U.S. with
Hyderabad: The Andhra Pradesh High Court today vacated a status quo order it had issued earlier on Sun Pharma-Ranbaxy merger process, paving the way for the pharma giants becoming a single entity.While vacating the status
New Delhi: The Supreme Court today asked the Andhra Pradesh High Court, which had passed an interim order staying the $4 billion merger of Ranbaxy with Sun Pharma, to decide the issue within two days.Hearing
New Delhi: Ranbaxy Laboratories will cease to exist as a company after completion of the $ 4 billion merger with Sun Pharmaceuticals, although its brands will be kept alive in over 100 markets. “The Ranbaxy entity
Top News
Latest News
